Numab and Kaken Pharmaceutical sign agreement for ND-081 for inflammatory bowel disease

Nov. 15, 2024

Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have signed a new collaboration and option agreement to develop ND-081, a multispecific antibody for the treatment of inflammatory bowel disease.

BioWorld Science Gastrointestinal Antibody

Today's news in brief

BioWorld

BioWorld briefs for Sept. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 22, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...

The domino effect of cutting mRNA vaccine research

BioWorld

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing...